Arvinas reported a net income of $82.9 million for the first quarter of 2025, a significant improvement from a net loss of $69.4 million in the same period last year, driven by a substantial increase in revenue to $188.8 million. The company also announced positive Phase 3 trial results for vepdegestrant and strategic reprioritization of its development plans, including workforce reductions to extend cash runway.
Reported positive topline results from the Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings.
Announced the re-prioritization of vepdegestrant development plan, removing two Phase 3 combination trials, to maximize patient benefit and shareholder value.
Initiated cost reductions, including a workforce reduction of approximately one-third, to extend the Company's cash runway into the second half of 2028.
Presented first-in-human data for ARV-102, showing blood-brain barrier penetration and central and peripheral LRRK2 degradation, with good safety and tolerability.
Arvinas expects its current cash, cash equivalents, and marketable securities to fund planned operating expenses and capital expenditure requirements into the second half of 2028. The company plans to present detailed VERITAC-2 results, share data with global regulatory authorities for potential filings, and continue clinical development for ARV-102 and ARV-393.
Analyze how earnings announcements historically affect stock price performance